GPP
VOR icon

Great Point Partners’s Vor Biopharma VOR Stock Holding History

Great Point Partners’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.2M Buy
1,750,000
+379,893
+28% +$5.36M 7.18% 2
2025
Q4 		$17.9M Buy
+1,370,107
New +$25.5M 5.81% 8

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Great Point Partners's VOR Position: Q1 2026 in Review

Great Point Partners increased its Vor Biopharma (VOR) stake by 28% in Q1 2026, buying an estimated $5.36M and bringing the position to 1,750,000 shares worth $31.2M. The position accounts for 7.18% of the portfolio, ranked #2.

Great Point Partners first reported a position in VOR in Q4 2025 and has held it in 2 quarters since. 80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

  • Great Point Partners held 1,750,000 shares of Vor Biopharma worth $31.2M as of Q1 2026.
  • Great Point Partners bought 379,893 Vor Biopharma shares in Q1 2026, an estimated $5.36M.
  • Vor Biopharma made up 7.18% of Great Point Partners's portfolio in Q1 2026, its #2 holding.
  • Great Point Partners first reported a position in Vor Biopharma in Q4 2025 and has held it in 2 quarters since.
  • 80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.